Is MiMedx Group, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for MiMedx Group, Inc. moved from attractive to fair, indicating a shift in its perceived value. The company appears to be fairly valued at this time. Key valuation ratios include a P/E ratio of 24, an EV to EBIT of 16.13, and an EV to EBITDA of 14.64, which suggest that while the company is not undervalued, it is also not significantly overvalued compared to its peers.
In comparison to its peers, MiMedx's P/E ratio of 33.09 is lower than LeMaitre Vascular, Inc.'s 49.77, indicating a more favorable valuation relative to that competitor, though it is higher than Alphatec Holdings, Inc., which has a negative P/E. Notably, the stock has shown strong performance over the past three years with a return of 164.26%, significantly outperforming the S&P 500's return of 76.66% over the same period. However, the year-to-date return of -20.06% compared to the S&P 500's 16.30% suggests recent challenges that may be affecting investor sentiment.